Jean-Jacques Kiladjian/LinkedIn
Dec 8, 2025, 14:46
Jean Jacques Kiladjian Presents 1st Results of the ROP-ET Study at ASH25
Jean Jacques Kiladjian, Head of Clinical Research Department of Inserm, shared on LinkedIn:
”Proud to have presented at American Society of Hematology ASH25 , on behalf of my co-investigators from 10 European countries, the first results of the ROP-ET study showing that ropeginterferon-alpha 2b is also an effective and safe treatment for patients with essential thrombocythemia ET who have no other therapeutic option.
At 12 months: 65% of durable (>3 months) complete hematologic response, no disease progression, only 1.5% of major thrombotic events, symptoms improvement in 62% of patients.”
Stay updated with Hemostasis Today.
-
May 6, 2026, 15:27Dear Thamasucharit: Insights on Pyruvate Kinase (PK) Deficiency
-
May 6, 2026, 14:58Insights on Acquired Hemophilia from ‘Bobby’ Duc Tran – Hemophilia of Georgia
-
May 6, 2026, 14:57Amanda S.: Strengthening the Global Network of Psychosocial Professionals in Bleeding Disorders at WFH 2026
-
May 6, 2026, 14:56Sierra Akers: Discussing the importance of Hemophilia Treatment Centers
-
May 6, 2026, 14:52Christy Abele: Helping People Craft Stories That Connect and Resonate at CHB Symposium
-
May 6, 2026, 14:46Joe Dawson: Follow-Up on a Patient with a History of an IVC Thrombus
-
May 6, 2026, 14:20Emmanuel J. Favaloro: Highlights of Global Haemostasis Testing in the Latest Issue
-
May 6, 2026, 14:02Abdul Mannan: Anemia in Myelofybrosis – Five Fires Behind One Falling Hb
-
May 6, 2026, 14:00Mona Alfaraj: Advancing Care in Inherited Platelet Disorders at 2nd International Hematology and Hemostasis Conference